Antonio Murgia1,2, Christine Hinz2, Sonia Liggi2, Jùlìa Denes2, Zoe Hall2, James West2, Maria Laura Santoru3, Cristina Piras3, Cristina Manis1, Paolo Usai4, Luigi Atzori3, Julian L Griffin2, Pierluigi Caboni5. 1. Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy. 2. Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, UK. 3. Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy. 4. Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Cagliari, Italy. 5. Department of Life and Environmental Sciences, University of Cagliari, Cagliari, Italy. caboni@unica.it.
Abstract
BACKGROUND: Inflammatory bowel disease is a group of pathologies characterised by chronic inflammation of the intestine and an unclear aetiology. Its main manifestations are Crohn's disease and ulcerative colitis. Currently, biopsies are the most used diagnostic tests for these diseases and metabolomics could represent a less invasive approach to identify biomarkers of disease presence and progression. OBJECTIVES: The lipid and the polar metabolite profile of plasma samples of patients affected by inflammatory bowel disease have been compared with healthy individuals with the aim to find their metabolomic differences. Also, a selected sub-set of samples was analysed following solid phase extraction to further characterise differences between pathological samples. METHODS: A total of 200 plasma samples were analysed using drift tube ion mobility coupled with time of flight mass spectrometry and liquid chromatography for the lipid metabolite profile analysis, while liquid chromatography coupled with triple quadrupole mass spectrometry was used for the polar metabolite profile analysis. RESULTS: Variations in the lipid profile between inflammatory bowel disease and healthy individuals were highlighted. Phosphatidylcholines, lyso-phosphatidylcholines and fatty acids were significantly changed among pathological samples suggesting changes in phospholipase A2 and arachidonic acid metabolic pathways. Variations in the levels of cholesteryl esters and glycerophospholipids were also found. Furthermore, a decrease in amino acids levels suggests mucosal damage in inflammatory bowel disease. CONCLUSIONS: Given good statistical results and predictive power of the model produced in our study, metabolomics can be considered as a valid tool to investigate inflammatory bowel disease.
BACKGROUND: Inflammatory bowel disease is a group of pathologies characterised by chronic inflammation of the intestine and an unclear aetiology. Its main manifestations are Crohn's disease and ulcerative colitis. Currently, biopsies are the most used diagnostic tests for these diseases and metabolomics could represent a less invasive approach to identify biomarkers of disease presence and progression. OBJECTIVES: The lipid and the polar metabolite profile of plasma samples of patients affected by inflammatory bowel disease have been compared with healthy individuals with the aim to find their metabolomic differences. Also, a selected sub-set of samples was analysed following solid phase extraction to further characterise differences between pathological samples. METHODS: A total of 200 plasma samples were analysed using drift tube ion mobility coupled with time of flight mass spectrometry and liquid chromatography for the lipid metabolite profile analysis, while liquid chromatography coupled with triple quadrupole mass spectrometry was used for the polar metabolite profile analysis. RESULTS: Variations in the lipid profile between inflammatory bowel disease and healthy individuals were highlighted. Phosphatidylcholines, lyso-phosphatidylcholines and fatty acids were significantly changed among pathological samples suggesting changes in phospholipase A2 and arachidonic acid metabolic pathways. Variations in the levels of cholesteryl esters and glycerophospholipids were also found. Furthermore, a decrease in amino acids levels suggests mucosal damage in inflammatory bowel disease. CONCLUSIONS: Given good statistical results and predictive power of the model produced in our study, metabolomics can be considered as a valid tool to investigate inflammatory bowel disease.
Authors: Sandra Vidal-Lletjós; Martin Beaumont; Daniel Tomé; Robert Benamouzig; François Blachier; Annaïg Lan Journal: Nutrients Date: 2017-03-21 Impact factor: 5.717
Authors: Aivett Bilbao; Bryson C Gibbons; Sarah M Stow; Jennifer E Kyle; Kent J Bloodsworth; Samuel H Payne; Richard D Smith; Yehia M Ibrahim; Erin S Baker; John C Fjeldsted Journal: J Proteome Res Date: 2021-08-12 Impact factor: 4.466
Authors: Katie A O'Brien; Ben D McNally; Alice P Sowton; Antonio Murgia; James Armitage; Luke W Thomas; Fynn N Krause; Lucas A Maddalena; Ian Francis; Stefan Kavanagh; Dominic P Williams; Margaret Ashcroft; Julian L Griffin; Jonathan J Lyon; Andrew J Murray Journal: BMC Biol Date: 2021-12-15 Impact factor: 7.364
Authors: Joseph Diab; Terkel Hansen; Rasmus Goll; Hans Stenlund; Einar Jensen; Thomas Moritz; Jon Florholmen; Guro Forsdahl Journal: Metabolites Date: 2019-11-27
Authors: Serena Longo; Marcello Chieppa; Luca G Cossa; Chiara C Spinelli; Marco Greco; Michele Maffia; Anna M Giudetti Journal: Proteomes Date: 2020-08-10